LithuaniaTuberculosis profile
Population  2014 2.9 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.22 (0.22–0.22) 7.7 (7.6–7.7)
Mortality (HIV+TB only) 0.02 (0.015–0.025) 0.69 (0.53–0.86)
Prevalence  (includes HIV+TB) 2.4 (1.1–4.2) 83 (39–145)
Incidence  (includes HIV+TB) 1.8 (1.7–2) 62 (57–68)
Incidence (HIV+TB only) 0.057 (0.05–0.064) 2 (1.7–2.2)
         
Case detection, all forms (%) 82 (75–89)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 14 (12–16) 49 (43–55)
MDR-TB cases among notified pulmonary
TB cases
160 (140–190) 140 (120–160)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 949   160
Pulmonary, clinically diagnosed 255   0
Extrapulmonary 109   8
       
Total new and relapse 1 481    
Previously treated, excluding relapses 126    
Total cases notified 1 607    
Among 1 481 new and relapse cases:
22 (1%) cases aged under 15 years; male:female ratio: 2.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 968 (102%) 294 (100%) 1 267
Laboratory-confirmed RR-/MDR-TB cases     279
Patients started on MDR-TB treatment ***     271
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 135 (71)
HIV-positive TB patients 36 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (80) 1 392
Previously treated cases, excluding relapse, registered in 2013 (37) 57
HIV-positive TB cases, all types, registered in 2013 (43) 21
RR-/MDR-TB cases started on second-line treatment in 2012 (41) 219
XDR-TB cases started on second-line treatment in 2012 (10) 52
Laboratories 2014  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 10.3
Drug susceptibility testing (per 5 million population) 10.3
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-30 Data: www.who.int/tb/data